PFE Jan 2023 75.000 put
| Previous Close | 25.30 |
| Open | 25.30 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 75.00 |
| Expire Date | 2023-01-20 |
| Day's Range | 25.30 - 25.30 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 34 |
- Reuters
UPDATE 1-Haleon not a party to U.S. litigation focused on Zantac - spokesperson
Haleon - GSK's recently spun off consumer health unit - is not a party to U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday. "We have never marketed Zantac in any form in the U.S., as Haleon or as GSK consumer healthcare," the spokesperson said, responding to Reuters querying a near-20% decline in Haleon's share price this week. The spokesperson said the drug has been sold by several companies since 1995 and that "may make third parties liable ahead of any Haleon exposure."
- Yahoo Finance
Novavax does not have a forecast for U.S. orders in 2022: CEO Erck
Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.
- Zacks
Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.
